AMG 436 / Amgen - LARVOL DELTA

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors (clinicaltrials.gov) - P1 | N=464 | Recruiting | Sponsor: Amgen | Trial completion date: Jul 2028 ➔ Feb 2032 | Trial primary completion date: Jul 2028 ➔ Jan 2030

dMMR • Mismatch repair • Monotherapy • MSI-H • Trial completion date • Trial primary completion date • Microsatellite Instability • Oncology • Solid Tumor • MSI

A multicenter phase 1/1b study of AMG 436 as monotherapy and combination therapy in patients with advanced MSI-H/dMMR solid tumors. (ASCO 2026) - "Enrollment is ongoing globally across North America, South America, Europe, and Asia-Pacific. Participants may remain on treatment for up to 2 years, with total trial duration including follow-up extending up to 5 years."

Clinical • Combination therapy • dMMR • First-in-human • IO biomarker • Metastases • Monotherapy • MSI-H • P1 data • Tumor mutational burden • Metabolic Disorders • Microsatellite Instability • Oncology • Solid Tumor • MSI • TMB • WRN

20250004: ??AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ? (clinicaltrialsregister.eu) - P1 | N=47 | Not yet recruiting | Sponsor: Amgen Inc.

dMMR • Mismatch repair • Monotherapy • MSI-H • New P1 trial • Microsatellite Instability • Oncology • Solid Tumor